I sat with my colleagues at a FDA Forum on partial gland ablation for prostate cancer a few days ago in New Orleans. I huddled in one corner trading snarky texts as speaker after speaker spoke over and under each other. Advocates advocated. Antagonists antagonized the advocates. Patient advocates pleaded for patient involvement — to be frank — for the wrong reasons. It was a government meeting writ large. Ennui prevailed.